NYSE:TMO
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.'s revenue grew 3.9% in fiscal 2025 to $44.6B while operating margin rose to 17.4%. Free cash flow was $6.3B, 14.1% of revenue, and the diluted share count fell 1.3%.Summary generated from Thermo Fisher Scientific Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$44.6B
Revenue growth+3.9%
Revenue, 5-yr CAGR+6.7%
Gross marginn/a
Operating margin17.4%
Net margin15.0%
ROIC9.0%
Return on equity13.0%
Debt / equity0.73
Free cash flow$6.3B
FCF margin14.1%
Share count change−1.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 39.2 | 44.9 | 42.9 | 42.9 | 44.6 |
| Operating income | 10.0 | 8.4 | 6.9 | 7.3 | 7.7 |
| Net income | 7.7 | 7.0 | 6.0 | 6.3 | 6.7 |
| Free cash flow | 6.8 | 6.9 | 6.9 | 7.3 | 6.3 |
Recent filings
- 4Insider transaction report
Sep 29, 2026 - 4Insider transaction report
Sep 29, 2026 - 10-QQuarterly report for the period ended Jun 27, 2026
Jul 31, 2026 - 8-KResults of operations and financial condition
Jul 23, 2026 - 8-KResults of a shareholder vote
May 26, 2026 - 10-QQuarterly report for the period ended Mar 28, 2026
May 1, 2026 - 8-KResults of operations and financial condition
Apr 23, 2026 - DEF 14AProxy statement
Apr 7, 2026